secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-08-10T20:17:18+00:00
Accession:  0001140361-26-032028
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma Q2 net income $123.2M on PRV sale; cash $283.7M, runway to Q2 2028
--------------------------------------------------------------------------------

- Net income $123.2M ($1.09 basic EPS) vs net loss $68.9M ($0.62 loss) in Q2 2025.
- Other income $178.8M includes $178.2M net from Rare Pediatric Disease PRV sale (closed June 12, 2026).
- RP-A501: all 3 initial Danon disease patients completed safety observation; no TMA or capillary leak.
- KRESLADI (LAD-I) FDA approved; commercial availability and patient onboarding expected Q4 2026.
- Cash $283.7M at June 30, 2026; expected to fund operations into Q2 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/0001140361-26-032028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/ef20079821_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer